title: Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma.
abstract: OBJECTIVE
  The role of high mobility group box chromosomal protein 1 in hepatocellular carcinoma is unknown. The aim of study was to evaluate contributions of high mobility group box chromosomal protein 1 in hepatocellular carcinoma, and analyse the correlation between high mobility group box chromosomal protein 1 and clinicopathologic outcomes.
  
  
  METHODS
  High mobility group box chromosomal protein 1 levels were analysed by Western blot analysis. Edmondson grade, TNM stage and the Cancer of the Liver Italian Program score were used as analysis variables.
  
  
  RESULTS
  The serum high mobility group box chromosomal protein 1 levels in hepatocellular carcinoma (84.2 +/- 50.4 ng/ml) was significantly higher than those in chronic hepatitis (39.8 +/- 10.5 ng/ml), liver cirrhosis (40.2 +/- 11.6 ng/ml) and healthy control (7.0 +/- 5.9 ng/ml, p < 0.0001, respectively), and positive correlation were found between high mobility group box chromosomal protein 1 and alpha-fetoprotein (r = 0.952, p < 0.0001), and between high mobility group box chromosomal protein 1 and the size of tumour (r = 0.904, p < 0.0001). High mobility group box chromosomal protein 1 were significant differences among Edmondson grade I, II, III, IV; TNM stage I, II, III, IV and Cancer of the Liver Italian Program score 0-1 points, 2-4 points, > 4 points (p < 0.0001, respectively).
  
  
  CONCLUSIONS
  These results suggest that high mobility group box chromosomal protein 1 may be a useful marker for evaluating the tumour stage and predicting prognosis in hepatocellular carcinoma. Targeting high mobility group box chromosomal protein 1 production or release might have potential approaches for hepatocellular carcinoma treatment.
authors.affiliation: Department of Gastroenterology, Qilu Hospital, School of medicine, Shandong University, Jinan 250012, PR China. dcbq@sohu.com
authors.forename: B-Q
authors.initials: BQ
authors.lastname: Cheng
authors.forename: C-Q
authors.initials: CQ
authors.lastname: Jia
authors.forename: C-T
authors.initials: CT
authors.lastname: Liu
authors.forename: X-F
authors.initials: XF
authors.lastname: Lu
authors.forename: N
authors.initials: N
authors.lastname: Zhong
authors.forename: Z-L
authors.initials: ZL
authors.lastname: Zhang
authors.forename: W
authors.initials: W
authors.lastname: Fan
authors.forename: Y-Q
authors.initials: YQ
authors.lastname: Li
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D024243:HMGB1 Protein / Q000097:blood*; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests
chemical_list: D015415:Biomarkers; D024243:HMGB1 Protein